Key Figures – Eurofins Scientific Group

according to International Financial Reporting Standards (IFRS)

Sales in € Million



Net operating cash flow in € Million



Average Number of Employees*



Number of countries



CAGR: Compound Annual Growth Rate

* FTE = Full Time Employees

Company Profile

A global leader in bio-analysis

Eurofins Scientific is a life sciences company operating internationally to provide a comprehensive range of analytical testing services to clients from a wide range of industries including the pharmaceutical, food and environmental sectors.

With 8,000 staff in more than 150 laboratories across 30 countries, Eurofins offers a portfolio of over 40,000 reliable analytical methods for evaluating the authenticity, origin, safety, identity, composition and purity of biological substances and products. The Group is committed to providing its customers with high quality services, accurate results in time and expert advice by our highly qualified staff.

The Eurofins Group is one of the global market leaders in this field of applied life sciences. It intends to pursue its dynamic growth strategy to expand both its technology portfolio and its geographic reach. Through R&D and acquisitions the Group draws on the latest developments in the field of biotechnology to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the demands of regulatory authorities around the world.

Shareholders' information in short

Listings

NYSE Euronext Paris (since IPO on 24.10.1997)
Frankfurter Wertpapierbörse/ XETRA Frankfurt (since SPO on 26.10.2000)

Segments/ Indexes

Paris: SBF 120 & Next 150, SRD & Compartment B
Frankfurt: Prime Standard/ Technology All Share

Industry Group/ Prime Sector

Pharma & Healthcare/Healthcare Providers

Codes

ISIN: FR 0000038259
Frankfurt: WKN 910251

Tickers

Paris: Reuters EUFI.LN, Bloomberg ERF FP
Frankfurt: ESF, EUFI.PA

Nominal Capital (as of 31.03.2010)

1,420,487.40 € (14,204,874 x 0.10 €)

Simplified Ownership Structure (31.03.2010)

46% Martin family
54% free float

Investor Relations

Eurofins Scientific Group
Phone: +32 2 769 7383
E-mail: ir@eurofins.com

Internet

www.eurofins.com

Disclaimer

THIS REPORT MAY CONTAIN FORWARD-LOOKING STATEMENTS AND ESTIMATES THAT INVOLVE RISKS AND UNCERTAINTIES. THE FORWARD-LOOKING STATEMENTS AND ESTIMATES CONTAINED HEREIN REPRESENT THE JUDGEMENT OF EUROFINS SCIENTIFIC AS OF THE DATE OF THIS RELEASE. THESE FORWARD-LOOKING STATEMENTS ARE NOT GUARANTEES FOR FUTURE PERFORMANCE, AND THE FORWARD-LOOKING EVENTS DISCUSSED IN THIS REPORT MAY NOT OCCUR. EUROFINS SCIENTIFIC DISCLAIMS ANY INTENT OR OBLIGATION TO UPDATE ANY OF THESE FORWARD-LOOKING STATEMENTS AND ESTIMATES. ALL STATEMENTS AND ESTIMATES ARE MADE BASED ON THE DATA AVAILABLE TO THE COMPANY AS OF THE DATE OF PUBLICATION, BUT NO GUARANTEE CAN BE MADE AS TO THEIR VALIDITY.

Operating and Financial Review and Prospects

Financial figures in this report were prepared based on the International Financial Reporting Standards (IFRS). All accounts are consolidated at the Eurofins Scientific Group level. The Company's auditors have conducted a limited review on these accounts.

Dear Shareholders,

Eurofins' first quarter of 2010 was, as usual, a relatively quiet one. Other than the impact of exceptionally cold weather, the results in the business during the quarter show nothing unexpected. Eurofins' revenues continue to grow in spite of the negative impact of this extreme weather and of discontinued activities. It is still too early in the year to see trends in specific markets but the underlying seasonality appears to be consistent with previous years. The Group remains on track in its finalisation of a five year modernisation and improvement plan, with the completion of three out of the remaining five major planned laboratory projects during the quarter. The first results of this modernisation plan are now visible.

The first quarter is normally seasonally quiet at Eurofins and 2010 was not a particular exception. Winter conditions always make it difficult to carry out environmental testing on soil and water and this year's winter was the coldest for decades and lasted for longer than usual. In several northern European countries, 2010 was reported as the coldest winter in 50 years with snow still covering the ground and preventing sampling in March. The environmental business was duly affected as the number of samples for all matrices dropped significantly, even compared to 2009. Sample numbers have now recovered but this significantly affected Group organic growth, which was flat in Q1, and profitability. Some pharma services laboratories, as in 2009, are seeing a delay in spending from sponsors although in general the market appears to be stable. In the food business results were solid, but as most activity is carried out in the second half of the year it is too early to make judgements on longer term trends.

As of the beginning of 2010, and as reported in the 2009 Annual Results, Eurofins has now brought almost 100% of its laboratories up to Group standards. This means that most of the laboratories have now implemented best-practice processes, state-of-the-art IT systems and have suitable management in place. Those that have not are mainly start up laboratories which are in various stages of the development process. To aid longer-term transparency and consistency, quarterly reporting will from now on focus on the Group results as a whole. The optic of two perimeters, designed to assist investors during a period of heavy investment and changes at the Group, has now become less meaningful, especially on a quarterly basis (Under Development revenues were only around €5m for Q1 2010).

Revenues for the first quarter were €149.1m, up 1% from €148.2m in Q1 2009, even after taking into account the impact of discontinued activities and of the severe weather. Clean EBITDA* increased to €13.3m in Q1 2010 from €12.6m in Q1 2009 (one-off/reorganisation costs of €2.8m Q1 2010, €1.9m in Q1 2009). After these one-off/reorganisation charges EBITDA in Q1 2010 was €10.5m, close to Q1 2009 reported numbers of €10.7m. Clean EBITAS** also increased to €3.6m from €3.5m in Q1 2009. After one-off/reorganisation charges EBITAS was slightly down at €0.8m (€1.6m Q1 2009). One-off/reorganisation costs for the quarter, consisting mainly of employee compensation and rent expenses for discontinued laboratories, were €2.8m (€1.9m Q1 2009), in line with the Group's stated plans to complete the consolidation of small, old or unprofitable laboratories into its large newly-modernised and expanded state-of-the-art laboratories.

Eurofins' cash generation continues to show positive trends and developed well in Q1 2010, in spite of the impact of the extreme winter on profitability. Net cash provided by operating activities increased by 41% to €9.2m (€6.5m Q1 2009) as a result of better profit before tax, higher depreciation and strong control over Net Working Capital. As a result of the near completion of the Group's five-year investment programme capital expenditure has started to move towards normal levels (€8.1m, 5.5% of revenues in Q1 2010, €10.9m, 7.3% of revenues in Q1 2009) and interest payments have also reduced as borrowing levels have decreased (€2.3m Q1 2010, €3.2m Q1 2009). Therefore Free Cash Flow*** for the first quarter 2010 was -€0.9m, compared to -€6.3m in Q1 2009. In fact excluding cash payments related to one-off/reorganisation costs that were paid in Q1 2010 of €6.1m (representing both utilisation of the provision, i.e. 2009 costs, and Q1 2010 one-off costs) the clean Free Cash Flow actually becomes positive at €5.2m. Cash out for one-off/reorganisation costs was €2.2m in Q1 2009, so Free Cash Flow for that period was -€4.1m (i.e. an improvement of €9.3m in Q1 2010 compared to the same quarter last year). There was no acquisition activity in Q1 2010 and 'Acquisition payments' of €0.6m relate to previous acquisitions (€5.9m Q1 2009, around half of which was deferred payments for previous acquisitions). The Balance Sheet therefore remains well structured. Net debt is €185.4m at 31 March 2010 (€183.7m 31 December 2009) and the covenants have remained the same and well within limits: net debt / equity at 0.9x and net debt to clean EBITDA at 2.0x, with maximums of 1.5x and 3.5x respectively.

Due to the reasons given above, Eurofins has no further views on how the markets will progress during 2010 and so will not for the moment give indications on the expected level of growth or profitability for the year. However, progress on internal projects continues to go well and the Group is looking forward to building on a strong base for operational improvement during the rest of 2010.

As usual I would like to thank all of our clients, employees and shareholders who contribute to our progress

Sincerely,

GMartin

Dr. Gilles G. Martin
CEO

* Clean EBITDA – Earnings before interest, tax, depreciation and amortisation, before one-off/reorganisation costs

** Clean EBITAS – earnings before interest, tax, amortisation of intangible assets and non-cash charge for share options, before one-off/reorganisation costs

*** Free Cash Flow – net cash flow provided by operating activities less cash used in investing activities, excluding acquisition payments and including interest payments

Revenues

In spite of discontinued activities and the worst winter in 50 years in several countries, Eurofins Group revenues increased during Q1 2010 to €149.1m, from €148.2m in Q1 2009. It is clear that, with a winter that was worse than in 2009, the impact on the main environmental markets was significant: Scandinavia, Germany and the Netherlands. Although small in absolute size, the “Other” segment continues to show good growth. As a result of all these effects, organic growth was flat in Q1 2010.

Breakdown of sales by region and as a % of sales:

€ million	Q1 2010	%	Q1 2009	%
Benelux	**17.5**	11.7	19.6	13.3
British Isles	**9.5**	6.4	8.4	5.7
France	**29.9**	20.1	28.9	19.5
Germany	**34.1**	22.9	31.9	21.5
North America	**15.4**	10.3	16.9	11.4
Scandinavia	**29.1**	19.5	30.3	20.4
Other	**13.6**	9.1	12.2	8.2
Total	**149.1**	100	148.2	100

Profitability

Profitability for the quarter was reasonable, although it was to some extent affected by the remaining one-off costs linked to the finalisation of the laboratory consolidation and modernisation programme. EBITDA was €10.5m (€10.7m Q1 2009), with a margin of 7.0% compared to 7.2% in Q1 2009, and “clean” EBITDA actually increased to €13.3m from €12.6m before one-off/reorganisation costs of €2.8m in Q1 2010 (€1.9m in Q1 2009). Reported EBITAS was €0.8m vs. €1.6m in Q1 2009. Control over cost of purchased materials and services remains tight (39.5% of revenues Q1 2010 vs 40.1% in Q1 2009) although personnel expenses were slightly higher as a percentage of revenues at 53.4%, compared to 52.5% in Q1 2009. Total one-off/reorganisation costs incurred for the quarter (mostly personnel and rent costs) were €2.8m (Q1 2009 €1.9m), which is consistent with an expected total expense for 2010 of up to €10m.

The net financial cost to the business decreased to €2.2m (€3.7m Q1 2009) as the Group’s borrowings have decreased significantly. Net attributable earnings during Q1 2010 were -€3.0m (-€2.9m Q1 2009).

Balance Sheet

Eurofins’ total assets at 31 March 2010 were €646.8m (€659.3m 31.12.2009). Net debt at the end of the period was €185.4m, compared to €183.7m at 31.12.2009, which is a major improvement compared to the €14m increase at the end of Q1 2009 from Year End 2008. The covenants have remained at the same level therefore, Net Debt / Equity being 0.9x and Net Debt / clean EBITDA at 2.0x (0.9x and 2.0x respectively at 31.12.2009). The cash balance at 31.03.2010 was €52.7m, down €1.6m on the 2009 year end balance of €54.4m but after a repayment of €5.0m in debt during the quarter.

Net Working Capital was 4.8% of revenues, compared to 4.8% at 31.12.2009 and again it was a strong improvement on the same period in 2009 (6.7% at 31.03.2009).

Cash Flow and Liquidity

The Group’s improvements in cash generation over the last 18 months continued into Q1 2010. Net cash provided by operating activities increased by 41% to €9.2m (€6.5m Q1 2009) and Free Cash Flow was -€0.9m (-€6.3m), a strong improvement in a traditionally weak quarter for cash generation. This is in spite of cash payments for one-off/reorganisation expenses (decrease in the provision and payment for 2010 costs) of €6.1m (€2.2 Q1 2009). This is due to a combination of improving profit before tax, lower capex, higher depreciation and the better Net Working Capital position mentioned above.

There was a cash outflow of €0.6m representing deferred payments for previous acquisitions (€5.9m Q1 2009). Capital expenditure during Q1 2010 was €8.2m, which was 5.5% of revenues, compared to €10.9m and 7.3% in Q1 2009. Eurofins still expects Full Year capex of approximately €50m.

Sales and Marketing

Eurofins food testing had a solid quarter. The Group’s contribution to increasing consumer protection through its scientific expertise was demonstrated by the involvement of its scientists in the advancement of regulations in allergen testing, moving towards simplification and homogeneity of tests.

Eurofins’ Pharma business made good progress in two major areas. In Quality Control a Master Service Agreement was signed with Sanofi-Aventis R&D Worldwide for a three-year period to provide quality control and clinical logistics services. In the Central Laboratory business, Eurofins concluded negotiations to become a strategic partner to a major pharmaceutical company. The Group expects that this will provide strong revenue streams in the medium term and should give it access to some potentially bigger contracts in the future. The Consumer Testing operations continue to provide innovative solutions for its customers. In China the Group expanded its portfolio to include 15 new Substances of Very High Concern (“SVHC”) that have been added to the EU’s REACH candidate list, along with leather testing capabilities that are also subject to REACH legislation in Europe and ‘Proposition 65’ testing in the USA. The Group also awarded its first Indoor Air Comfort Gold Certificate to Knauf Insulation, certifying Knauf’s new ECOSE range of insulation products according to the VOC (Volatile Organic Compounds) indoor air quality emissions regulations.

Although as mentioned above, the weather conditions made for a very difficult first quarter in Environmental testing, internal progress continued to be made. The transfer of operations from Oosterhout continues to go smoothly and from February all clean water testing at Eurofins in the Netherlands is being done at the Group’s Heerenveen laboratory.

Acquisitions and Geographic Expansion

There is nothing of note to report for the first quarter in terms of acquisitions and geographic expansion, as the Group continues to focus on internal improvements. The M&A policy continues to be one of low-key activity, simply continuing to monitor the marketplace and focusing on deals of strategic relevance only. The Group also remains focused on achieving its profitability objectives its existing portfolio of countries and start ups and so no new developments occurred in these areas in the first quarter of 2010.

Investment, R&D and Infrastructure

During the first quarter, the Group completed work on three (out of five) of its remaining laboratories that form the final phase of the programme to modernize and expand Eurofins’ network. Environmental laboratories in Wesseling (near Cologne, Germany) and Barneveld (The Netherlands) enable the Group to consolidate some sites and improve profitability in that business and a new consumer testing laboratory in Shanghai (China) is one of several new facilities that Eurofins has in China and is part of the Group's dedication to satisfying its customers' needs for a complete range of testing around the World.

Other News

Dr. Markus Brandmeier has been promoted to the Group Executive Committee as Executive Vice President Food Testing CEE and Latin America. Dr. Brandmeier joined Eurofins in 2005 and previously held similar responsibilities as head of the Group's food testing operations based in Germany.

Employees

The overall average weighted number of Full Time Employees for the period to 31 March was 7,075, compared to 7,192 at 31 December 2009 and 7,020 at Q1 2009. Headcount for the Group at 31 March was 7,989 (7,652 at 31.03.2009), down from 8,089 at 31.12.2009.

Country	**31.03.2010**	31.12.2009	31.03.2009
Benelux	**702**	761	775
British Isles	**447**	482	479
France	**1,338**	1,405	1,376
Germany	**1,834**	1,725	1,667
North America	**620**	629	628
Scandinavia	**1,144**	1,245	1,265
Other	**990**	946	830
Total	**7,075**	7,192	7,020

Employee numbers are weighted average "Full time equivalents" (FTE), i.e. the figures are weighted by the time that (acquired) laboratories are fully consolidated in the Group.

Total personnel costs for the Group, including social security and pension costs, were €79.6m, which represents 53.4% of Group revenues for the three months (Q1 2009 €77.9m, 52.5%).

Capital Structure

The Martin family, either directly or through their holding in Analytical Bioventures SCA, holds 46% of the shares in Eurofins Scientific and 53% of the voting rights as of the end of Q1 2010. The remainder is free float.

The summary of Directors' Holdings as at 31 March 2010 is shown in the table below:

As of 31.03.2010	No. of Shares	No. of Stock Options
Gilles G. Martin	1	0
Valérie Hanote	1	0
Wicher R. Wichers	25,001	8,500
Yves-Loïc Martin	14,546	0

Analytical Bioventures SCA, which is controlled by Gilles and Yves-Loïc Martin, holds 6,559,570 shares.

Consolidated Financial Statements

Consolidated Profit and Loss Statement

January 1, 2010 to March 31, 2010

€ Thousand	Q1/2010	Q1/2009
Revenues	**149,107**	**148,242**
Cost of purchased materials and services	-58,970	-59,448
Personnel expenses	-79,622	-77,899
Other operating income and expenses, net	-60	-210
EBITDA	10,455	10,685
Depreciation and amortisation	-9,625	-9,135
EBITAS*	**830**	**1,550**
Non cash accounting charge for stock options (S.O.)	-539	-547
Impairment of goodwill and amortisation intangible assets related to acquisitions	-268	-357
EBIT after non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions	23	646
Finance income	335	639
Finance costs	-2,573	-4,341
Financial result	-2,239	-3,702
Share of (loss)/ profit of associates	62	27
Result before income taxes	-2,154	-3,029
Income tax expense	-393	0
Net profit for the period	**-2,547**	**-3,029**
Attributable to:		
Equity interest	-2,984	-2,868
Minority interest	437	-161
Earnings per share (basic) in € - Total	-0.21	-0.20
Earnings per share (basic) in € - attributable to hybrid capital investors	0.14	0.14
Earnings per share (basic) in € - attributable to equity holders	-0.35	-0.35
Earnings per share (diluted) in € - Total	-0.19	-0.19
Earnings per share (diluted) in € - attributable to hybrid capital investors	0.13	0.13
Earnings per share (diluted) in € - attributable to equity holders	-0.32	-0.32
Weighted average shares outstanding (basic)	14,205	14,165
Weighted average shares outstanding (diluted)	15,434	15,298

* EBITAS : EBIT before non cash accounting charge for S.O., impairment of goodwill and amortisation of intangible assets related to acquisitions

Statement of Comprehensive income

As of March 31, 2010

€ Thousand	Q1/2010	Q1/2009
Net profit for the period	**-2,547**	**-3,029**
Currency translation differences	3,612	3,202
Financial instruments	-468	-2,191
Other comprehensive income for the period, net of tax	**3,144**	**1,011**
Total comprehensive income for the period	**597**	**-2,018**
Attributable to:		
Equity interest	146	-1,812
Minority interest	451	-206

Consolidated Balance Sheet

As of March 31, 2010

€ Thousand	31.03.2010	31.12.2009
Property, plant and equipment	134,250	135,002
Goodwill	241,503	239,313
Other intangible assets	29,528	29,943
Investments in associates	2,321	2,260
Financial assets, trade and other receivables	5,966	5,487
Deferred tax asset	14,113	15,643
Derivative financial instruments	0	0
Total non current assets	**427,681**	**427,648**
Inventories	7,973	7,769
Trade accounts receivable	131,425	145,298
Prepaid expenses and other current assets	23,408	20,826
Corporate tax receivable	3,595	3,398
Cash and cash equivalents	52,740	54,360
Total current assets	**219,141**	**231,651**
Total assets	**646,822**	**659,299**
Share capital	1,421	1,421
Other reserves	56,494	52,882
Hybrid capital	100,000	100,000
Retained earnings	37,350	42,321
Shareholders' equity – part of the Group	195,265	196,624
Minority interest	6,542	6,410
Total shareholders' equity	**201,807**	**203,034**
Borrowings	94,344	97,283
OBSAR Bonds	118,128	118,057
Derivative financial instruments	4,923	4,455
Deferred tax liability	3,261	7,127
Account payable on investment	19,720	20,603
Pension accrual	12,549	12,411
Provisions for other liabilities and charges	15,970	18,495
Total non current liabilities	**268,895**	**278,431**
Borrowings	25,656	22,735
Trade accounts payable	44,779	50,558
Advance payments received and deferred revenues	15,867	16,671
Corporate tax due	7,234	7,597
Account payable on investment	1,594	1,359
Other current liabilities	80,990	78,914
Total current liabilities	**176,120**	**177,834**
Total liabilities and shareholders' equity	**646,822**	**659,299**

Consolidated Cash Flow Statement

January 1, 2010 to March 31, 2010

€ Thousand	Q1/2010	Q1/2009
Cash flows from operating activities		
Result before income taxes	**-2,154**	**-3,029**
Adjustments for:		
Depreciation and amortisation	9,894	9,492
Increase/ decrease in provisions and accruals	-2,849	96
Losses/ gains on the disposal of fixed assets, investments in associates	-231	-191
Losses/ gains on the disposal of subsidiaries	0	0
Non cash accounting charge for stock options	511	515
Financial income and expense, net	2,392	3,742
Expense/ income from investments (equity method)	-62	-27
Derivative financial instruments – income statement	0	0
Change in net working capital	4,948	-4,085
Cash generated from operations	**12,449**	**6,513**
Income taxes paid	-3,275	-3
Net cash provided by operating activities	**9,174**	**6,510**
Cash flows from investing activities		
Acquisitions of subsidiaries, net of cash acquired	-633	-5,856
Proceeds from sale of a subsidiary, net of cash transferred	20	0
Purchase of property, plant and equipment	-7,049	-9,490
Purchase of intangible assets	-1,101	-1,403
Proceeds from sale of property, plant and equipment	129	820
Purchase net of sales of investments and financial assets	17	-47
Interest received	315	455
Net cash used in investing activities	**-8,302**	**-15,521**
Cash flows from financing activities		
Proceeds from issuance of share capital	4	55
Proceeds from short or long term borrowings	709	786
Cash repayments of amounts borrowed	-5,021	-21,530
OBSAR Bonds	0	71
Cash repayments of OBSAR Bonds	0	0
Hybrid capital issue	0	0
Dividends to shareholders	0	0
Dividends to minority interest	-60	0
Earnings paid to hybrid capital investors	0	0
Interest paid	-2,349	-3,180
Net cash provided by financing activities	**-6,717**	**-23,798**
Net effect of currency translation in cash and cash equivalents	264	195
Net increase (decrease) in liquid funds	**-5,581**	**-32,614**
Cash and cash equivalents and bank overdrafts at beginning of period	52,254	127,854
Cash and cash equivalents and bank overdrafts at end of period	**46,673**	**95,240**

Consolidated Statement of Changes in Equity

As of March 31, 2010

€ Thousand	Shareholders' equity part of the Group				Minority interest	Total Equity
	Share capital	Other reserves	Hybrid Capital	Retained earnings		
Balance at January 1, 2009	**1,416**	**49,086**	**100,000**	**62,084**	**6,532**	**219,118**
Currency translation differences	0	3,168	0	8	26	3,202
Financial instruments	0	0	0	-2,191	0	-2,191
Minority interest transfer	0	0		71	-71	0
Total income / expense recognised directly in equity	0	3,168	0	-2,112	-45	1,011
Net profit	0	0	0	-2,868	-161	-3,029
Total income recognised in 2009	0	3,168	0	-4,980	-206	-2,018
Treasury stock	0	0	0	0	0	0
Deferred taxes on net investments	0	0	0	-132	0	-132
Non cash accounting charge for stock options	0	0	0	515	0	515
Distribution on Hybrid Capital	0	0	0	-2,020	0	-2,020
Issue of share capital	1	55	0	0	0	56
Dividends	0	0	0	0	0	0
Minority interest arising on business combinations	0	0	0	0	214	214
Balance at March 31, 2009	**1,417**	**52,309**	**100,000**	**55,467**	**6,540**	**215,733**
Balance at January 1, 2010	**1,421**	**52,882**	**100,000**	**42,321**	**6,410**	**203,034**
Currency translation differences	0	3,608	0	-10	14	3,612
Financial instruments	0	0	0	-468	0	-468
Minority interest transfer	0	0	0	0	0	0
Total income / expense recognised directly in equity	0	3,608	0	-478	14	3,144
Net profit	0	0	0	-2,984	437	-2,547
Total income recognised in 2010	0	3,608	0	-3,462	451	597
Treasury stock	0	0	0	0	0	0
Deferred taxes on net investments	0	0	0	0	0	0
Non cash accounting charge for stock options	0	0	0	511	0	511
Deferred distribution on Hybrid Capital	0	0	0	-2,020	0	-2,020
Issue of share capital	0	4	0	0	0	4
Dividends	0	0	0	0	-60	-60
Minority interest arising on business combinations	0	0	0	0	-259	-259
Balance at March 31, 2010	**1,421**	**56,494**	**100,000**	**37,350**	**6,542**	**201,807**

Interim Notes

General

We inform you that these Interim Notes are summarised.

1. Accounting policies

Eurofins condensed interim financial statements for the 3 month period ending 31st March 2010 have been prepared according to IAS 34 – Interim financial reporting standard as adopted by the European Union.

As condensed interim financial statements, they do not include all information required by IFRS framework for the preparation of annual financial statements and have to be read in relation with the Group consolidated financial statements prepared for the year-end 2009 in accordance with International Financial Reporting Standards (IFRS) as adopted by the European Union.

As described below, the accounting policies applied are consistent with the policies applied in the financial statements for the accounts closed at the end of 2009.

Taxes on income in the interim periods are accrued using the tax rate that would be applicable to expected total annual earnings.

The following standards, amendments and interpretations to published standards are mandatory for accounting periods since 1 January 2010. The Group didn't early adopt any of these standards, amendments and interpretations in previous reporting periods.

- IFRS 2 (amendment), 'Group cash-settled and share-based payment transactions'
- IFRS 3 (Revised), 'Business combinations'. The revised IFRS 3 recommends the use of the acquisition method for business combinations and is significantly different from the previous standard. All price adjustments to the purchase a business are to be classified as recorded at fair value at the acquisition date. After a period of 12 months, any adjustments will be booked in the income statement. Taking control of a subsidiary by step-acquisition conditions the recognition of a gain/ loss on the percentage already owned or the loss of control generates the recognition of a gain/ loss on the percentage still held. These different elements increase the volatility on the net profit of the Group.
  There is a choice on an acquisition-by-acquisition basis to measure the full or partial goodwill. Transaction costs should be booked as expenses. The Group has applied the revised IFRS 3 prospectively to business combinations since 1 January 2010.
- IFRS 5 (amendment), 'Non current assets held for sale and discontinued operations'
- IFRS 7 (Amendments,) 'Financial Instruments: Disclosures'
- IFRS 8 (Amendments), 'Operating segments'
- IAS 1R (amendment), 'Presentation of financial statements'
- IAS 7 (amendment), 'Statement of Cash Flows'
- IAS 10 (amendment), 'Events After the Balance Sheet Date'
- IAS 12 (amendment), 'Income Taxes'
- IAS 16 (amendment), 'Property, Plant and Equipment'
- IAS 17 (amendment), 'Leases'
- IAS 21 (amendment), 'The Effects of Changes in Foreign Exchange Rates'
- IAS 27 (Revised), 'Consolidated and separate financial statements',
- IAS 28 (Amendment), 'Investments in associates' and
- IAS 31 (Amendment), 'Interest in joint ventures' (effective from July 2009).
- IAS 32 (amendment), 'Financial Instruments: Presentation'
- IAS 33 (amendment), 'Earnings per Share'
- IAS 34 (amendment), 'Interim Financial Reporting'
- IAS 36 (amendment), 'Impairment of Assets'
- IAS 37 (amendment), 'Provisions, Contingent Liabilities and Contingent Assets'
- IAS 38 (amendment), 'Intangible assets'.
- IAS 39 (amendment),
- IFRIC 9, 'Reassessment of embedded derivatives'
- IFRIC 16, 'Hedges of a net investment in a foreign operation'
- IFRIC 17, 'Distribution of non-cash assets to owners'
- IFRIC 18, 'Transfers of assets from customers'.

Other Interpretations of existing standards that are not yet effective and not relevant for the Group's operations

- IFRIC 14, 'Prepayments of a minimum funding requirements'
- IFRIC 19, 'Extinguishing financial liabilities with equity instruments'

The additional disclosures required will be presented for the first time in the 2010 annual financial statements as they are not material for an understanding of the current interim period.

2. Segment information

Geographical segments

Although the Group's business is managed on a worldwide basis, it operates in eight main geographical areas. These are Benelux, France, Germany, North America, Scandinavia, British Isles (United Kingdom + Republic of Ireland) Other European countries and Other Rest of the World countries.

€ Thousand Revenues	Q1/2010	Q1/2009
Benelux	17,497	19,637
France	29,892	28,896
Germany	34,109	31,883
North America	15,420	16,945
Scandinavia	29,094	30,297
British Isles	9,505	8,380
Other European Countries	9,943	9,704
Other countries	3,647	2,500
Total	149,107	148,242

Revenues are based on the production country. For confidentiality reasons, the operating income by geographical areas is not provided.

3. Change in the scope 2010

No new companies were acquired by the Eurofins Group during the first quarter of 2010.

4. Balance sheet impact of the change of scope

During the first three months of 2010 the Company continued to acquire small percentages of minority interests held in Group companies. The Group also continued to pay amounts due to former-shareholders of purchased companies

The fair values of assets and liabilities are as follows:

€ Thousand	Q1/2010
Property, plant and equipment	360
Intangible assets	74
Goodwill and intangible assets related to an acquisition	830
Investments	0
Financial assets	16
Current assets excluding Cash	300
Corporate tax receivable	0
Cash	-20
Current liabilities	-479
Corporate taxes due	0
Borrowings	0
Account payable on investment	-1,368
Deferred taxes	-127
C/A not consolidated	0
Pension accrual	-36
Provisions for risks	-228
Losses/ gains on the disposal of subsidiaries	297
Shareholders equity	0
Minority interest	-252
Total purchase price paid to date	**-633**
Less cash	20
Cash outflow on change of scope	**-613**

Divided into:	
Cash outflow on acquisition	-633
Proceeds from disposals of a subsidiary, net of cash transferred	20

5. Contingencies

The contingencies are described in more detail in the Annual Report 2009 in the Note 4.2.
The liabilities/ borrowings listed below are already included in the Group's balance sheet. The following table only repeats these amounts when these borrowings are secured by covenants or securities on assets.

€ Thousand	**31.03.2010**	**31.12.2009**
Bank borrowings secured over buildings and assets	18,132	19,072
Leases secured over buildings and assets*	5,638	5,868
Bank borrowings secured by covenants and financial assets	0	0
Bank borrowings & OBSAR secured by covenants	204,776	207,524
Total	228,546	232,464

* Lease liabilities are effectively secured as the rights to the leased asset revert to the lessor in the event of default.

As March 31st 2010 the cash and cash equivalents are € 46,673 k.

Detail of specific contingencies linked to acquisitions:

Rights to acquire or sell additional shares of a company have been signed at a formula price already fixed to be exercised during the period 2010-2015. The contingencies linked to the right to acquire or sell shares in this company (not yet booked in the consolidated balance sheet) are estimated at an amount of € 0.16m.

6. Changes in Equity

Share capital: At March 31st 2010, the total number of ordinary shares is 14.205 million shares with a par value of € 0.10 per share. All issued shares are fully paid.
During the first three months of 2010, the share capital increased by 350 new shares by exercise of employee stock options.
As at 31st March 2010, the Company did not own any of its own shares (number of own shares at December 31, 2009: 0).

Financial instruments:
To hedge the Group's exposure to interest rates fluctuations related to the OBSAR bonds, the Group has swapped its variable interest rate against a fixed rate.
Principal amount hedged with a fixed rate: € 100m.
The fair value 31st March 2010 of the financial instruments is estimated at an expense of € 4,923k.

Hybrid Bonds:
The structure of the hybrid bond ensures that it is recognized as a component of equity in accordance with IAS 32. For this reason, the tax-deductible interest payments are not included in interest expense, but accounted for in the same way as dividend obligations to shareholders. The interest expense accounted for during the first three months amounts to € 2,021k.

7. Stock option plans

Stock options are granted to directors and employees. Movements in the number of share options outstanding are as follows (amounts in thousands):

At beginning of the year	930
Options granted	0
Options exercised	0
Options expired	0
At end of the period	**930**

8. Cash and Cash equivalents

€ Thousand	**31.03.2010**
Cash and cash equivalents - Balance Sheet	52,740
Operational overdrafts	-6,067
Cash and cash equivalents and bank overdrafts at end of period - Cash flow	46,673

9. Post closing events

No significant events have happened since the closing

PricewaterhouseCoopers Audit
34, place Viarme
BP 90928
44009 Nantes Cedex 1

HLP Audit
4, rue Amédée Ménard
BP 32532
44325 Nantes Cedex 3

STATUTORY AUDITORS' REVIEW REPORT ON THE FINANCIAL INFORMATION FROM JANUARY 1^{ST} TO MARCH $31^{ST,}$ 2010

To the Shareholders,

EUROFINS SCIENTIFIC SE
Rue Pierre Adolphe Bobierre
Boîte postale 42301
44323 Nantes cedex 3

This is a free translation into English of the Statutory Auditors' review report issued in French and is provided solely for the convenience of English speaking readers. This report should be read in conjunction with, and construed in accordance with, French law and professional auditing standards applicable in France.

At your request and as statutory auditors of your company, we hereby report to you on the accompanying condensed interim consolidated financial statements of Eurofins Scientific SE Company for the period January 1^{st} to March 31^{st}, 2010.

These condensed interim consolidated financial statements are the responsibility of the Company's management. Our role is to express a conclusion on these financial statements based on our review.

We conducted our review in accordance with professional standards applicable in France. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with professional standards applicable in France and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated financial statements are not prepared, in all material respects, in accordance with IAS 34 - the standard of IFRSs as adopted by the European Union applicable to interim financial information.

Neuilly-sur-Seine and Nantes, May 6, 2010

The Statutory Auditors

PricewaterhouseCoopers Audit — HLP Audit

Benoit PINOCHE — ***Jacques HERON***